Trial site

Cangzhou Central Hospital

Cangzhou, Hebei 061012, ChinaNot linked to an institution yet

26running trials
14closed trials

The trials here

What the 40 trials at this site are about, from their registry records.

Conditions: Stroke8 trials
Lung cancer5 trials
Coronary artery disease4 trials
COPD2 trials
IgA nephropathy2 trials
Macular degeneration2 trials
Metastatic breast cancer2 trials
Obesity2 trials
Prostate cancer2 trials
Type 2 diabetes2 trials
Atopic dermatitis (eczema)1 trial
Cervical cancer1 trial
and 9 more
Phase: Phase 321 trials
Phase 26 trials
Phase 11 trial
Phase 1/21 trial
Phase 2/31 trial
Phase 41 trial
Status: Completed14 trials
Recruiting10 trials
Active, not recruiting8 trials
Not yet recruiting8 trials
Lead sponsor: Capital Medical University3 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 trials
Shanghai Henlius Biotech3 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 trials
Harbin Medical University2 trials
and 23 more

Running trials

Not yet recruiting
Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients
NCT07869797· Mundipharma (China) Pharmaceutical Co. Ltd· Source
Contact: Geng Zhang
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Sichen Wei
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625· Harbin Medical University· Source
Contact: Jun Zhang
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· RemeGen Co., Ltd.· Source
Contact: Yongfeng Yang
Recruiting
Smartwatch-based Intervention for Cardiovascular Health (SWITCH)
NCT07372729· Beijing Anzhen Hospital· Source
Contact: Xiaoyang Sun
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xiang Song, Master
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493· Phase 2· Kunming Pharmaceuticals, Inc.· Source
Contact: Duo Gao, bachelor
Active, not recruiting
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335· Phase 1· Shanghai Henlius Biotech· Source
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Contact: US Biogen Clinical Trial Center
Not yet recruiting
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Not yet recruiting
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Active, not recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Recruiting
Modified Tumor-free Techniques Operation to Cervical Cancer
NCT06836869· Peking Union Medical College Hospital· Source
Contact: Shikai Liu, professor
Active, not recruiting
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883· Phase 2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
Normobaric Oxygen in AIS Transferred for EVT
NCT06666764· Phase 3· Capital Medical University· Source
Contact: Jing Wang
Recruiting
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
NCT06548971· Phase 3· Capital Medical University· Source
Contact: Zhen Hong, M.D.
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
NCT07515079· Phase 3· Bio-Thera Solutions· Source
Contact: Zhixue Wang
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）
NCT06559241· Phase 3· Capital Medical University· Source
Contact: Yongchang Liu
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654· Phase 2/3· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source
Contact: Jieqiong Liu
Recruiting
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
NCT06569524· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Sichen Wei, Master
Active, not recruiting
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287· Phase 3· RemeGen Co., Ltd.· Source
Active, not recruiting
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679· Amgen· Source
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
NCT05461339· Phase 3· BioDlink Biopharm Co., Ltd.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Not yet recruiting
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source
Contact: Jun Zhang

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Stroke4 recruiting
Coronary artery disease2 recruiting
Lung cancer2 recruiting
Prostate cancer2 recruiting
Cervical cancer1 recruiting
Diabetic eye disease1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Gastric and oesophageal cancer1 recruiting
IgA nephropathy1 recruiting
Neuromyelitis optica (NMOSD)1 recruiting
Obesity1 recruiting

Closed trials

Completed
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Completed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Completed
HTA of NIVATS Based on RWE
NCT06574295· Fudan University· Source
Completed
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT06481085· Phase 2· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source
Completed
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
NCT06037889· Phase 3· Peking Union Medical College Hospital· Source
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
NCT06350890· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source
Completed
Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
NCT06429384· Phase 2· Beijing Tiantan Hospital· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
Ultrasound-Guided Stellate Ganglion Block Plus Propofol for Perimenopausal Insomnia With Anxiety
NCT07384468· Xiaochen Ji· Source
Completed
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05142722· Phase 3· NewAmsterdam Pharma· Source
Completed
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
NCT05003245· Phase 3· Shanghai Henlius Biotech· Source
Completed
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
NCT05359068· Phase 3· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Completed
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
NCT04624854· Phase 4· Harbin Medical University· Source
Completed
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
NCT04830826· The First Affiliated Hospital of Guangzhou Medical University· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error